TY - JOUR
T1 - Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorder
AU - Banaschewski, Tobias
AU - Soutullo, César
AU - Lecendreux, Michel
AU - Johnson, Mats
AU - Zuddas, Alessandro
AU - Hodgkins, Paul
AU - Adeyi, Ben
AU - Squires, Liza A.
AU - Coghill, David
PY - 2013
Y1 - 2013
N2 - Optimal management of attention deficit hyperactivity disorder (ADHD) aims not only to ameliorate patients' symptoms, but also to improve health-related quality of life (HRQL) and functioning. A pivotal, 7-week, randomized, double-blind, placebo-controlled, phase III study in children and adolescents in ten European countries demonstrated that the stimulant prodrug lisdexamfetamine dimesylate (LDX) is an effective and generally well-tolerated treatment for symptoms of ADHD.
AB - Optimal management of attention deficit hyperactivity disorder (ADHD) aims not only to ameliorate patients' symptoms, but also to improve health-related quality of life (HRQL) and functioning. A pivotal, 7-week, randomized, double-blind, placebo-controlled, phase III study in children and adolescents in ten European countries demonstrated that the stimulant prodrug lisdexamfetamine dimesylate (LDX) is an effective and generally well-tolerated treatment for symptoms of ADHD.
U2 - 10.1007/s40263-013-0095-5
DO - 10.1007/s40263-013-0095-5
M3 - Article
C2 - 23893527
SN - 1179-1934
JO - CNS Drugs
JF - CNS Drugs
ER -